Literature DB >> 23273681

Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.

Vitaly Margulis1, Shahrokh F Shariat, Yury Rapoport, Michael Rink, Daniel D Sjoberg, Nizar M Tannir, E Jason Abel, Stephen H Culp, Pheroze Tamboli, Christopher G Wood.   

Abstract

BACKGROUND: There is limited evidence to guide patient selection for cytoreductive nephrectomy (CN) following the diagnosis of metastatic renal cell carcinoma (mRCC).
OBJECTIVE: Given the significant variability in oncologic outcomes following surgery, we sought to develop clinically relevant, individualized, multivariable models for the prediction of cancer-specific survival at 6 and 12 mo after CN. The development of this nomogram will better help clinicians select patients for cytoreductive surgery. DESIGN, SETTING, AND PARTICIPANTS: We identified 601 consecutive patients who underwent CN for kidney cancer at a single tertiary cancer center. INTERVENTION: CN for mRCC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The development cohort was used to select predictive variables from a large group of candidate predictors. The discrimination, calibration, and decision curves were corrected for overfit using 10-fold crossvalidation that included stepwise variable selection. RESULTS AND LIMITATIONS: With a median follow-up of 65 mo (range: 6-199) for the entire cohort, 110 and 215 patients died from kidney cancer at 6 and 12 mo after surgery, respectively. For the preoperative model, serum albumin and serum lactate dehydrogenase were included. Final pathologic primary tumor stage, nodal stage, and receipt of blood transfusion were added to the previously mentioned parameters for the postoperative model. Preoperative and postoperative nomograms demonstrated good discrimination of 0.76 and 0.74, respectively, when applied to the validation data set. Both models demonstrated excellent calibration and a good net benefit over large ranges of threshold probabilities. The retrospective study design is the major limitation of this study.
CONCLUSIONS: We have developed models for accurate prediction of cancer-specific survival after CN, using either preoperative or postoperative variables. While these tools need validation in independent cohorts, our results suggest that the models are informative and can be used to aid in clinical decision making.
Copyright © 2012. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23273681      PMCID: PMC4378834          DOI: 10.1016/j.eururo.2012.11.040

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  28 in total

Review 1.  Role of cytoreductive nephrectomy in the era of targeted therapy for renal cell carcinoma.

Authors:  Paul L Crispen; Michael L Blute
Journal:  Curr Urol Rep       Date:  2012-02       Impact factor: 3.092

2.  The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.

Authors:  Toni K Choueiri; Wanling Xie; Christian Kollmannsberger; Scott North; Jennifer J Knox; J Geoffrey Lampard; David F McDermott; Brian I Rini; Daniel Y C Heng
Journal:  J Urol       Date:  2010-11-12       Impact factor: 7.450

3.  Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie.

Authors:  Sylvie Negrier; Frédéric Gomez; Jean-Yves Douillard; Alain Ravaud; Christine Chevreau; Murielle Buclon; David Perol; Christine Lasset; Bernard Escudier
Journal:  World J Urol       Date:  2005-02-12       Impact factor: 4.226

4.  Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?

Authors:  Stephen H Culp; Nizar M Tannir; E Jason Abel; Vitaly Margulis; Pheroze Tamboli; Surena F Matin; Christopher G Wood
Journal:  Cancer       Date:  2010-07-15       Impact factor: 6.860

Review 5.  Comparisons of nomograms and urologists' predictions in prostate cancer.

Authors:  Phillip L Ross; Claudia Gerigk; Mithat Gonen; Ofer Yossepowitch; Ilias Cagiannos; Pramod C Sogani; Peter T Scardino; Michael W Kattan
Journal:  Semin Urol Oncol       Date:  2002-05

6.  Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis.

Authors:  John M Hollingsworth; David C Miller; Stephanie Daignault; Brent K Hollenbeck
Journal:  Cancer       Date:  2007-05-01       Impact factor: 6.860

7.  Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma.

Authors:  Ken-Ryu Han; Allan J Pantuck; Matthew H T Bui; Oleg Shvarts; Danielo G Freitas; Amnon Zisman; Bradley C Leibovich; Frederick J Dorey; Barbara J Gitlitz; Robert A Figlin; Arie S Belldegrun
Journal:  Urology       Date:  2003-02       Impact factor: 2.649

8.  Decision curve analysis: a novel method for evaluating prediction models.

Authors:  Andrew J Vickers; Elena B Elkin
Journal:  Med Decis Making       Date:  2006 Nov-Dec       Impact factor: 2.583

9.  Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.

Authors:  Robert J Motzer; Jennifer Bacik; Lawrence H Schwartz; Victor Reuter; Paul Russo; Stephanie Marion; Madhu Mazumdar
Journal:  J Clin Oncol       Date:  2004-02-01       Impact factor: 44.544

10.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Authors:  Daniel Y C Heng; Wanling Xie; Meredith M Regan; Mark A Warren; Ali Reza Golshayan; Chakshu Sahi; Bernhard J Eigl; J Dean Ruether; Tina Cheng; Scott North; Peter Venner; Jennifer J Knox; Kim N Chi; Christian Kollmannsberger; David F McDermott; William K Oh; Michael B Atkins; Ronald M Bukowski; Brian I Rini; Toni K Choueiri
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544

View more
  26 in total

1.  Impact of smoking status on survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.

Authors:  Harun Fajkovic; Shahrokh F Shariat; Tobias Klatte; Mihai Dorin Vartolomei; Ilaria Lucca; Aurélie Mbeutcha; Morgan Rouprêt; Alberto Briganti; Pierre I Karakiewicz; Vitaly Margulis; Michael Rink; Mesut Remzi; Christian Seitz; Karim Bensalah; Romain Mathieu
Journal:  World J Urol       Date:  2016-02-15       Impact factor: 4.226

2.  Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy.

Authors:  Hironori Fukuda; Toshio Takagi; Tsunenori Kondo; Kazuhiko Yoshida; Satoru Shimizu; Yoji Nagashima; Kazunari Tanabe
Journal:  Int J Clin Oncol       Date:  2018-01-05       Impact factor: 3.402

3.  Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma.

Authors:  Ross J Mason; Lori Wood; Anil Kapoor; Naveen Basappa; George Bjarnason; Stephen A Boorjian; Rodney H Breau; Ilias Cagiannos; Michael A S Jewett; Pierre I Karakiewicz; Wassim Kassouf; Christian Kollmannsberger; Aly-Khan A Lalani; Jean-Baptiste Lattouf; Luke T Lavallée; Stephen Pautler; Nicholas Power; Patrick Richard; Alan So; Simon Tanguay; Ricardo A Rendon
Journal:  Can Urol Assoc J       Date:  2019-06       Impact factor: 1.862

4.  Renal cell carcinoma: standards and controversies.

Authors:  Tobias Klatte; Grant D Stewart
Journal:  World J Urol       Date:  2018-12       Impact factor: 4.226

5.  Are Allogeneic Blood Transfusions Associated With Decreased Survival After Surgery for Long-bone Metastatic Fractures?

Authors:  Stein J Janssen; Yvonne Braun; John E Ready; Kevin A Raskin; Marco L Ferrone; Francis J Hornicek; Joseph H Schwab
Journal:  Clin Orthop Relat Res       Date:  2015-01-31       Impact factor: 4.176

6.  Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus.

Authors:  Ricardo A Rendon; Anil Kapoor; Rodney Breau; Michael Leveridge; Andrew Feifer; Peter C Black; Alan So
Journal:  Can Urol Assoc J       Date:  2014-05       Impact factor: 1.862

7.  External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.

Authors:  Lorenzo Marconi; Roderick de Bruijn; Erik van Werkhoven; Christian Beisland; Kate Fife; Axel Heidenreich; Anil Kapoor; Jose Karam; Caroline Kauffmann; Tobias Klatte; Boerje Ljungberg; Surena Matin; Daniel Sjoberg; Michael Staehler; Grant D Stewart; Simon Tanguay; Robert Uzzo; Sarah Welsh; Lori Wood; Chris Wood; Axel Bex
Journal:  World J Urol       Date:  2018-08-01       Impact factor: 4.226

Review 8.  New challenges in kidney cancer management: integration of surgery and novel therapies.

Authors:  Javier Puente Vázquez; T Alonso Gordoa; J Moreno; L Poma; E Diaz Rubio; A Gomez; J Blazquez; J L Gonzalez Larriba
Journal:  Curr Treat Options Oncol       Date:  2015-03

9.  Current landscape of cytoreductive nephrectomy: who, when, and why?

Authors:  Jiping Zeng; Alfredo Harb-De la Rosa; Juan Chipollini
Journal:  Ann Transl Med       Date:  2019-07

10.  The difficulty in selecting patients for cytoreductive nephrectomy: An evaluation of previously described predictive models.

Authors:  Brandon J Manley; Daniel M Tennenbaum; Emily A Vertosick; James J Hsieh; Daniel D Sjoberg; Melissa Assel; Nicole E Benfante; Seth A Strope; Eric Kim; Jozefina Casuscelli; Maria F Becerra; Jonathan A Coleman; Abraham Ari Hakimi; Paul Russo
Journal:  Urol Oncol       Date:  2016-08-24       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.